Juniper Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Juniper Biosciences is a private, pre-revenue biotech company developing a pipeline of radiopharmaceutical theranostics. The company leverages a platform that links radioisotopes to high-specificity ligands to enable precise diagnosis and treatment of cancers, aiming to minimize side effects and maximize therapeutic impact. With a team possessing decades of combined experience in the field, Juniper is advancing multiple programs from pre-clinical stages towards the clinic. Its vision is to become a leader in nuclear medicine innovation by improving patient access to novel radiopharmaceuticals.

Oncology

Technology Platform

Platform for developing targeted radiopharmaceutical theranostics by linking radioisotopes to high-specificity ligands for precise diagnosis and treatment of diseases.

Opportunities

The radiopharmaceutical market is growing rapidly, validated by recent FDA approvals.

Juniper has the opportunity to develop best-in-class agents for established targets or pioneer novel theranostics for high-unmet-need cancers, potentially positioning itself as an attractive partner or acquisition target.

Risk Factors

Key risks include scientific failure of its platform or pipeline candidates, intense competition from large pharma and other biotechs, the complex logistics and high costs of radiopharmaceutical development, and reliance on future fundraising as a pre-revenue company.

Competitive Landscape

The radiopharmaceutical competitive landscape is intense, featuring dominant players like Novartis and Bayer, alongside numerous clinical-stage biotechs. Juniper must differentiate through superior targeting, novel isotopes, or innovative biology to secure a market position.

More companies in Radiopharmaceuticals →More companies in United States →